.

Survey on Eltrombopag Role in Management of ITP and Aplastic Anemia

Dear Sir or Madam, please take a few minutes of your time to complete the following questionnaire.

Secured
Survio
Create a survey
1

The incidence of ITP was approximately 3.3/100,000 person-years in adults.. most adults (70–80%) show a chronic course.. Based on your clinical experience, Does this data matching your clinical experience? what is the percentage of adult patients with Chronic IPT?

Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol 2010;85:174-80 Moulis G, Palmaro A, Montastruc JL, Godeau B, Lapeyre-Mestre M, Sailler L. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood 2014;124:3308-15.
2

How do you perceive the role of Eltrombopag in the treatment of ITP and aplastic anemia?

Rate the role of Eltrombopag in the treatment of ITP and aplastic anemia.
3

In your opinion, what are the key patient profiles that benefit the most from Eltrombopag treatment?

Select the key patient profiles that you believe benefit the most from Eltrombopag treatment.
4

How would you position TPO-RA in the international guidelines for ITP and aplastic anemia treatment?

Select the most appropriate positioning of TPO-RA in the international guidelines for the treatment of ITP and aplastic anemia.
5

Can you share a specific clinical experience involving Eltrombopag and its impact on a patient with ITP or aplastic anemia?

Please provide a detailed account of a clinical experience involving Eltrombopag treatment and its outcomes in a patient with ITP or aplastic anemia.
6

How do you assess the safety profile of Eltrombopag in long-term use for ITP and aplastic anemia?

Rate the safety profile of Eltrombopag in long-term use for ITP and aplastic anemia.
7

Which factors influence your decision to prescribe Eltrombopag to a patient with ITP or aplastic anemia?

Select the factors that play a significant role in your decision to prescribe Eltrombopag for patients with ITP or aplastic anemia.
8

What challenges have you faced in the clinical use of Eltrombopag for ITP or aplastic anemia?

Please identify the main challenges you have encountered during the clinical use of Eltrombopag for ITP or aplastic anemia.
9

How would you rate the efficacy of Eltrombopag in achieving sustained remission in ITP or aplastic anemia?

Rate the efficacy of Eltrombopag in achieving sustained remission in patients with ITP or aplastic anemia.
10

In your experience, what are the key advantages of using Eltrombopag compared to other treatments for ITP and aplastic anemia?

Select the key advantages that Eltrombopag offers over other treatments for ITP and aplastic anemia based on your experience.
Create a survey